Sorrento Therapeutics Inc

NASDAQ:SRNE  
8.08
-0.20 (-2.42%)
4:51:37 PM EDT: $8.10 +0.02 (+0.25%)
Products

Sorrento Adds Mesenchymal Stem Cell Program (Msc) That Has Been Cleared For A Phase 1 Trial By The FDA To The Pipeline Of Covid-19 Focused Rescue Therapies

Published: 10/12/2020 21:44 GMT
Sorrento Therapeutics Inc (SRNE) - Sorrento Adds Mesenchymal Stem Cell Program (msc) That Has Been Cleared for a Phase 1 Trial by the FDA to the Pipeline of Covid-19 Focused Rescue Therapies.
Sorrento Therapeutics Inc - Entered Into an Exclusive License Agreement With Personalized Stem Cells.
Sorrento - Agreement to Acquire Global Rights to Its Adipose Derived Mesenchymal Stem Cells for Patients Suffering From Ards Associated With Covid-19.
Sorrento - to Assume Responsibility for Executing Phase 1 Trial, Targeted to Enroll About 20 Hospitalized Covid-19 Patients in California.